LNTH Lantheus Holdings, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
22.46
PEG
—
P/B
5.50
P/S
4.34
EV/EBITDA
16.78
DCF Value
$602.54
FCF Yield
5.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.5%
Operating Margin
18.8%
Net Margin
18.0%
ROE
24.3%
ROA
11.9%
ROIC
10.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $377.3M | $118.4M | $— |
| Q4 null | $406.8M | $54.1M | $— |
| FY null | $1.54B | $233.6M | $— |
| Q3 null | $384.0M | $27.8M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$103.50
Target (Median)
$102.50
Target Range
$94.00 - $115.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
-0.08
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.